• Loading stock data…

ICPT

A Closer Look At CNAT’s “Failed” Clinical Study

Introduction Conatus Pharmaceuticals (Nasdaq: CNAT) recently released highly anticipated top-line data from their Encore-PH clinical trial. The study investigated the efficacy and safety of … [Read more...] about A Closer Look At CNAT’s “Failed” Clinical Study

GALT is Primed for Acquisition or Partnership

Overview Galectin Therapeutics (NASDAQ GALT $5.96) is a leader in the development of a treatment for  Non-Alcoholic SteatoHepatitis, an unmet medical need worth billions. Their star drug … [Read more...] about GALT is Primed for Acquisition or Partnership